Skip to main navigation Skip to search Skip to main content

NOSTRA-Feasibility study: A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer..

Project Details

Short titleNOSTRA-Feasibility study: A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer..
StatusActive
Effective start/end date1/01/18 → 31/12/26

Funding

  • ROCHE PRODUCTS LIMITED